Evidence Explorer / MS-N215 / Unsupported cure claims and safety / Appraised November 2, 2026
Gc protein-derived macrophage-activating factor (GcMAF) has been sold as an immune treatment for cancer. The most dramatic cancer papers were retracted, the remaining reports are uncontrolled, and a medicines regulator warned about unlicensed products made from unsuitable plasma under unacceptable conditions.
Evidence at a glance
- Published evidence: small uncontrolled reports used serum nagalase and clinical observations rather than reliable comparative cancer outcomes.
- Retractions: prominent metastatic breast- and colorectal-cancer publications were retracted.
- Regulatory safety: the UK MHRA seized unlicensed product made from plasma labeled unsuitable for human or drug use and raised sterility and contamination concerns.
- Cancer-control conclusion: no reliable evidence establishes response, recurrence prevention or survival benefit.
- Evidence label: unreliable and retracted evidence with serious product-quality risk.
What was studied
A 2013 retrospective, open-label report described 20 people with heterogeneous advanced cancers receiving weekly injections. Nineteen had lower serum nagalase values, but the study had no control group and did not provide a reliable basis for causal tumor-response or survival claims.
An earlier colorectal-cancer report claimed eradication of metastases in eight patients using nagalase as a surrogate. PubMed labels the paper as retracted and links the 2014 retraction notice. A related metastatic breast-cancer paper was also retracted.
What this evidence cannot establish
A fall in nagalase is not validated proof that a tumor has shrunk or disappeared. Uncontrolled clinical impressions cannot separate treatment effects from concurrent oncology care, selection, natural history or measurement bias.
Published reports involving one preparation cannot establish the identity, sterility or effectiveness of products sold under the same name. No standard clinical dose or quality specification is established.
Practical safety context
The MHRA found unlicensed GcMAF made from plasma labeled not for administration to humans or use in drug products. Inspectors cited unacceptable manufacturing conditions, equipment and possible contamination.
Injected blood-derived products can carry infection, immune and contamination risks. Patients who used an unregulated product should tell their oncology team and seek advice about symptoms or appropriate testing.
Questions for the care team
- Is the product licensed, independently tested and traceable to a validated manufacturing lot?
- Are claimed outcomes based on imaging and standard oncology endpoints rather than nagalase alone?
- Have retractions and regulator warnings been disclosed?
Sources
- UK MHRA safety warning
- Uncontrolled 20-patient report — PMID 24179708
- Retracted colorectal-cancer article — PMID 18058096
- Colorectal-cancer retraction notice — PMID 25297451
Source note: Regulator and PubMed records were checked. PubMed explicitly labels the colorectal article retracted and links the retraction notice; the breast-cancer paper is also linked to a retraction notice. The uncontrolled 2013 report does not establish efficacy. No correction or new validating randomized trial was identified on November 2, 2026.
This record is educational. GcMAF should not replace proven cancer treatment, and unlicensed injectable products can pose serious quality and infection risks.
